Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INSPIRE: ipilimumab with nivolumab in molecular-selected metastatic castration-resistant prostate cancer
2020-001240-25Phase 2Active
- Sponsor
- Radboudumc
- Start
- Jul 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2 trial of nivolumab and ipilimumab in metastatic castration-resistant prostate cancer (mCRPC) (2 cohorts), sponsored by Radboudumc. Primary endpoint: Primary efficacy endpoint: disease control rate >6 months. Started Jul 2020; status: active.
02
Drugs
nivolumabipilimumab
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on 2020-001240-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001240-25.